Excited to scale the the work in #AI on #digitalpath #pathomics with support from @MayoPlatform @MayoClinic @MayoCancerCare @MayoClinicNeuro @GFarrugiaMD 🙏🏻 for the vision

Many things. We can gain many insights from a model like this about treatment response, survival, and patient outcomes. If we can combine images like Radiomics and Pathomics with clinical text and documentation, we can unlock many unanswered questions and generate many hypotheses. Who will respond to which treatments? Who is the best candidate for immunotherapy and why? Who is the best candidate for tyrosine kinase inhibitors and why? Why can certain patients survive deadly cancers in rare cases, and what makes them unique? The list goes on and on. AI here becomes a powerful research and hypothesis-generating partner

🔓 Open Access Online & in press! "Pathomic Analysis of 5-Year Surveillance Biopsies as Predictors of Kidney Allograft Loss," by Sarder et al amjtransplant.org/article/S1… #KidneyTransplant #Pathomics #Nephrology #TransplantResearch

なるほど〜。 "Pathomics highlighted tubulointerstitial inflammation and glomerular tuft deformation as predictors of corticosteroid response."

Great seeing familiar faces like @SaynaNorouzi on Day 2 of AI in Nephrology. A strong focus on pathomics & computational nephropathology, alongside thoughtful and impressive trainee poster presentations! @wisit661 #AIinNephrology

AACR 2026: Lung Cancer Immunotherapy Response Predicted by Pathomics AI Model The study included patients from @UTMDAnderson, @MayoClinic, @GustaveRoussy, and the Phase III Lung-MAP S1400I trial. #LungCancer #ArtificialIntelligence #proteomics hubs.li/Q04d3NgB0

At @AACR, excited to see how AI is shaping the future of cancer care. Nice work from Rukhmini Bandyopadhyay (@UTMDAnderson) on a deep learning pathomics platform to help predict #immunotherapy response in lung cancer. #AACR26 Read more at aacr.org/about-the-aacr/news…

Path-IO represents the first deep learning-based pathomics biomarker rigorously validated across international real-world cohorts and a phase III randomized clinical trial, said Bandyopadhyay. #AACR26

A deep learning pathomics platform called Path-IO applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in lung cancer patients, according to a study presented at #AACR26 by Rukhmini Bandyopadhyay, PhD. brnw.ch/21x1LmZ

@AACR Press Conference #2 Oncologytube.com will be posting the video soon! @OmarNadeemMD BCMA-directed CAR T-cell Therapy May Be Effective Against High- risk Smoldering Multiple Myeloma A Machine Learning Model that Uses DNA Methylation Patterns May Help Identify the Origin of Cancers of Unknown Primary A Deep Learning Pathomics Platform May Help Predict Response to Immunotherapy in Lung Cancer Patients

Excited for the 2026 Dr. Robert Gillies ML Workshop in Cancer (Oct 15–16, Moffitt Cancer Center, Tampa FL) Learn AI in oncology—from radiomics & pathomics to genAI, NLP, and foundation models, ethics. Hackathon is a bonus! Register now! #AIinHealthcare cvent.me/KyRmez?sms=2

Dr Laura Barisoni on “Pathomics” at the Big Data Lab session #ISNWCN

💥Highly recommended publication: "Utilizing a Pathomics Biomarker to Predict the Effectiveness of Bevacizumab in Ovarian Cancer Treatment" 🔗mdpi.com/2306-5354/11/7/678 🏫@UofOklahoma 📌#OvarianCancer #MedicalAI #CancerPrediction

🌍 WCN’26開催まであと16日！ 🗓 3/29 9:25–10:55｜Room 315 Big Data Lab: Using Open Kidney Disease Data Resources for Research 🔹 Pathomicsによる組織解析 🔹 マルチスケールデータ統合 🔹 シングルセル・空間データ解析 🔹 Nephroseq・TranSMART オープンデータを活用した研究の可能性を紹介

RNA editing isn’t just noise. It defines immune subtypes in bladder cancer. -> AIRE-driven subtypes reveal who benefits from immunotherapy -> Radiomics pathomics enable noninvasive prediction nature.com/articles/s41746-0…

🌟🔬 What’s next after platinum immunotherapy in advanced #NSCLC without actionable genomic alterations? @JCO_ASCO Oncology Practice 🔹 Most patients without AGAs progress within 12 months after first-line chemo-IO 🔹 Docetaxel ± ramucirumab remains the standard 2L option after platinum ICI 🔹 Anti-angiogenic ICI strategies show mixed results post-progression 🔹 Bispecific antibodies (ivonescimab) emerge as a promising new class 🔹 AI-driven pathomics & radiomics may refine future treatment selection 🔹 CAR-T and novel immune strategies remain investigational in this setting ➡️ A clear unmet need persists beyond chemo-IO, underscoring the importance of biomarker-driven development and resistance biology. 🔗 ascopubs.org/doi/10.1200/OP-… #NSCLC #LungCancer #Immunotherapy #ADC #BispecificAntibodies #OncologyPractice #JCO #MedTwitter #OncoTwitter

AI-based pathomics in kidney diseases: progress and application tandfonline.com/doi/full/10.… @WeAreTandF @tandfnewsroom @tandfonline @tandfmedicine

A machine-learning–based pathomics nomogram demonstrated robust discrimination & calibration in predicting recurrence-free survival in patients with localized primary gastric and small intestinal GISTs after complete surgical resection. acsjournals.onlinelibrary.wi… @OncoAlert

Multimodal AI has arrived in breast ca! An avalanche of compelling presentations at #SABCS25 -multimodal ICM w/pathomics is prognostic and provides better performance for late recurrence than ODx in TAILORx -check out Rapid Fire 3 for more on TAILORx, NSABP B-20, NSABP B-42